Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer
Adding daily oral ibandronate to adjuvant endocrine therapy did not prolong disease-free survival or reduce bone recurrences at 8.5 years of follow-up.
Adding daily oral ibandronate to adjuvant endocrine therapy did not prolong disease-free survival or reduce bone recurrences at 8.5 years of follow-up.
Edinburgh International Culture Summit, which takes place Friday 26 – Sunday 28 June 2023, has announced its key youth contributors, as part of its commitment to putting young voices at the heart of…
Elizabeth DeWolf interviews mathematician Cathy O’Neil about her latest book on the shame industrial complex….
An overview of exoplanet missions and research at NASA’s Jet Propulsion Laboratory
/PRNewswire/ — University of Maryland Medicine, the joint enterprise of the University of Maryland School of Medicine, the University of Maryland Medical…